Name: Trifluridine (NSC 75520)
Brand: Selleck Chemicals
SKU: S1778
Availability: InStock
Rating: 5 (8 reviews)

Jump to

Quality Control

Batch: Purity: 99.96%

99.96

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase
Other Thymidylate Synthase Inhibitors	Raltitrexed

Solubility

In vitro
Batch:

DMSO : 59 mg/mL (199.18 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 59 mg/mL

Ethanol : 59 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.950mg/ml (9.96mM)	Taking the 1 mL working solution as an example, add 50 μL of 59 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.730mg/ml (2.46mM)	Taking the 1 mL working solution as an example, add 50 μL of 14.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	296.2	Formula	C₁₀H₁₁F₃N₂O₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	70-00-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	NSC 529182, NSC 75520, Viroptic, Trifluorothymidine, TFT			SMILES	C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	DNA synthesis
In vitro	Trifluridine (NSC 75520) inhibits proliferations of mouse bone marrow cells and human colorectal carcinoma cells implanted to nude mice dose-dependently. It also inhibits colony formation of bone marrow cells in a concentration-dependent manner. This compound and 2'-deoxy-5-fluorouridine (FdUrd) are incorporated into DNA with different efficiencies due to differences in the substrate specificities of TK1 and DUT, causing abundant FTD incorporation into DNA. FTD-treated cells shows differing nuclear morphologies compared to FdUrd-treated cells. It further inhibits proliferations of mouse bone marrow cells and human colorectal carcinoma cells implanted to nude mice dose-dependently.
In vivo	Trifluridine (NSC 75520) has significantly fewer swabs positive for HSV-1 than the untreated eyes in the infected rabbits. This compound has increased antitumor activity and is incorporated into DNA more effectively than continuously infused Trifluridine in mice. It gradually accumulates in tumor cell DNA, in a TPI-independent manner, and significantly delays tumor growth and prolonged survival in mice, compared to treatment with 5-FU derivatives. Furthermore, it results in significantly lower viral titers, fewer HSV-1-positive eyes/total during the treatment period, lower keratitis scores, fewer eyes with keratitis/total, and a shorter time to resolution of keratitis in the New Zealand rabbit ocular model.
References	[1] https://pubmed.ncbi.nlm.nih.gov/26084259/ [2] https://pubmed.ncbi.nlm.nih.gov/25901475/ [3] https://pubmed.ncbi.nlm.nih.gov/24018612/ [4] https://pubmed.ncbi.nlm.nih.gov/2539342/ [5] https://pubmed.ncbi.nlm.nih.gov/25230742/ [6] https://pubmed.ncbi.nlm.nih.gov/9950596/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06197425	RECRUITING	Colon or Upper Rectum Adenocarcinoma	Centre Hospitalier Universitaire Dijon	2026-05-07	PHASE3
NCT07381764	NOT_YET_RECRUITING	Metastatic Colorectal Cancer (CRC)	Gruppo Oncologico Italia Meridionale	2026-03-30	PHASE2
NCT07270991	RECRUITING	Metastatic Oesogastric Adenocarcinoma	Federation Francophone de Cancerologie Digestive	2025-12-15	PHASE3
NCT05719558	RECRUITING	Advanced Solid Tumors	Astellas Pharma Global Development, Inc.	2023-03-13	PHASE1
NCT06856837	RECRUITING	Metastatic Colorectal Cancer	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	2025-10-27	PHASE2
NCT07286695	NOT_YET_RECRUITING	Metastatic Colorectal Cancer (CRC); Colorectal Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2025-12-31	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Trifluridine (NSC 75520) Thymidylate Synthase inhibitor

Chemical Structure

Molecular Weight: 296.2